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The recent rise in the prevalence of chronic allergic diseases among children has increased disease
burden and reduced quality of life, especially for children with comorbid allergic diseases. Pre-
dicting the occurrence of allergic diseases can help prevent its onset for those in high risk groups.
Herein, we aimed to construct prediction models for asthma, atopic dermatitis (AD), and asthma-
AD comorbidity (also known as atopic march) using a genome-wide association study (GWAS) and
family history data from patients of Korean heritage. Among 973 patients and 481 healthy con-
trols, we evaluated single nucleotide polymorphism (SNP) heritability for each disease using
genome-based restricted maximum likelihood (GREML) analysis. We then compared the perfor-
mance of prediction models constructed using Least Absolute Shrinkage and Selection Operator
(LASSO) and penalized ridge regression methods. Our results indicate that the addition of family
history risk scores to the prediction model greatly increase the predictability of asthma and
asthma-AD comorbidity. However, prediction of AD was mostly attributable to GWAS SNPs.
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cially in children who have developed comorbid
allergic diseases, known as atopic march.1
Predicting allergic disease occurrence can help
prevent those in high risk groups from
developing diseases. Unfortunately, the
predictability and validity of constructed models
differ greatly, and most have not proven clinically
useful.2 Genome-wide prediction of childhood
asthma based on highest-ranked single nucleotide
polymorphisms (SNPs) has suggested that the
genetic origins of asthma are diverse.3 Herein, we
aimed to construct prediction models for asthma,
atopic dermatitis (AD), and asthma-AD comorbid-
ity using a genome-wide association study (GWAS)
and family history data from patients of Korean
heritage. We evaluated SNP heritability for each
disease and compared the performance of our
prediction models built upon distinct factors.
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and sensitization were included in the study, along
with 481 healthy controls (Supplementary Table 1).
Among those with allergic disease, there were 498
patients with asthma, 632 patients with AD, and
157 patients with asthma-AD comorbidity. All
allergic disease subjects had confirmed allergic
sensitization, defined by allergen-specific IgE
levels >0.7 kUA/L to at least 1 of the 9 common
food or airborne allergens. AD was diagnosed by
pediatric allergists for patients with a SCORAD
(SCORing Atopic Dermatitis) index of over > 30.
Asthma was confirmed based on consistent respi-
ratory symptoms verified by a physician, the pres-
ence of either 12% increase in forced expiratory
volume in 1 second (FEV1) in response to a bron-
chodilator, or bronchial hyperresponsiveness
defined as  20% decrease in FEV1 with inhalation
of <16 mg/mL methacholine. DNA was extracted
from whole blood samples, and genome-wide
SNPs and genetic variant information were identi-
fied using the Illumina HumanCoreExome-24 v1.0
BeadChip kit (Illumina Inc., San Diego, CA, USA).
Method specifications including confirmation
standards for allergic sensitization, quality control,
and imputation methods for genotype data are
provided in the Supplementary Methods and
Supplementary Table 2.
To investigate the overall influence of genotype
on each disease, we calculated the proportion of
phenotypic variance explained by SNPs using
genome-based restricted maximum likelihood
(GREML) analysis4 with Genome-wide Complex
Trait Analysis (GCTA) 64 version 1.92.0 beta 2
software (http://cnsgenomics.com/software/gcta/).
For this analysis, SNPs were pruned using a sliding
window protocol with a maximum of 500 kbp and
linkage disequilibrium (LD) composite measure
threshold of 0.2, and the genetic relationship ma-
trix was calculated. Sex and 10 genotype principal
component (PC) scores were included as cova-
riates. We then used Least Absolute Shrinkage and
Selection Operator (LASSO) and penalized ridge
regression to develop prediction models for each
disease. Risk scores of each disease were calcu-
lated as described by Gim et al5 using the disease
status of relatives and their kinship coefficients. A
positive family history was considered if family
members, including patient parents and siblings
only, had asthma, AD, allergic rhinitis, or foodallergy; otherwise, the family history was
considered negative. SNPs were selected using
absolute best linear unbiased prediction (BLUP)
values. BLUPs were calculated by GCTA64 after
adjustment for sex and 10 genotype PC scores,
and the top 100, 500, 1000, 5000, and 10 000
SNPs with the largest absolute BLUPs were
selected. The list of SNPs used for the models
with best performance for each disease is shown
in Supplementary Table 3. Prediction model
performance was evaluated by comparing the
area under the curve (AUC) of receiver operating
characteristic (ROC) curves obtained by 10-fold
cross validation. The detailed procedures for
both analyses are provided in the Supplementary
Methods.
Table 1 shows the estimated SNP heritability by
GREML analysis. Genotyped SNPs accounted for
54.88% (p ¼ 0.0714), 4.64% (p > 0.4), and
12.75% (p > 0.4) of the phenotypic variance of
AD, asthma, and asthma-AD comorbidity, respec-
tively. Our SNP heritability estimates might be
smaller than the previous studies and SNP herita-
bility tends to be smaller than heritability esti-
mated by the family-based samples.6 The
difference may also be related with the
difference in subject ethnicity and the
genotyping chip designed mainly for use in
Caucasians.
Addition of the family history risk scores signifi-
cantly increased prediction model performance for
asthma and asthma-AD comorbidity, as shown in
Fig. 1. For asthma, AUC increased from 0.661 to
0.691 (DeLong test p ¼ 7.14  103) for the
LASSO prediction model, and from 0.661 to
0.698 (p ¼ 8.48  103) for the ridge regression
model. Similarly, the prediction model
performance for asthma-AD comorbidity
increased significantly with addition of the family
history risk scores (LASSO: 0.539 to 0.614,
p ¼ 9.01  104; ridge regression: 0.509 to 0.568,
p ¼ 0.0424). Prediction model performance also
increased for AD, but not as significantly (LASSO:
0.666 to 0.675, p ¼ 0.360; ridge regression: 0.638
to 0.650, p ¼ 0.408). The number of SNPs used for
each model and the sensitivity and specificity es-
timates at the inflection points are presented in
Supplementary Table 4.
Fig. 1 Vertical bar plots of AUCs of the (a) LASSO and (b) ridge regression prediction models with or without the addition of family history
risk scores. The top 100, 500, 1,000, 5,000, and 10,000 SNPs selected with best linear unbiased prediction values (BLUPs) were separately




Asthma 0.0464 0.3805 0.4411
Atopic dermatitis 0.5488 0.3812 0.0714
Asthma-AD comorbidity 0.1275 0.4456 0.4212
Table 1. Estimated SNP heritability for each disease calculated with GREML analysis. Hsnp2, SNP heritability at the liability scale. SE, standard error.
AD, Atopic Dermatits, P-values were calculated by likelihood ratio tests
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asthma to UK Biobank data, we achieved an AUC
of 0.567 (p < 2.2  1016). The odds ratio (OR) of
the polygenic risk score (PRS) estimated from the
logistic regression was 10.129 (p ¼ 0.02). This
analysis is described in the Supplementary
Methods. However, we could not validate the
prediction models for AD and asthma-AD comor-
bidity, and those combined with the family history
risk scores using UK Biobank data, because it
contained insufficient family history information.
Our results show that the addition of family
history risk scores increased the overall prediction
model performance for asthma, suggesting that
family factors other than genotype contribute to
the predictive power of the model. Asthmaheritability is only partly explained by genetic var-
iants, with the range of heritability estimates vary-
ing from 35% to 95% in previous studies.7
Similarly, the predictive value of positive family
history alone has been reported to range from
11% to 37%.8 Although sole use of family history
may be unreliable for asthma predictability, its
addition to GWAS may improve prediction
model performance. Further, the addition of
family history risk scores greatly increased the
predictability of asthma-AD comorbidity, despite
the initial AUC being around 0.50. On the other
hand, prediction of AD may be mostly attributable
to GWAS SNPs.
Family history risk scores can explain additional
family factors such as shared environmental effects
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GWAS. Several limitations are present in our study,
including the retrospective collection of family
history from medical records and the relatively
small sample size of the GWAS cohort. Addition-
ally, an age factor might have contributed to bias,
since the AD group was younger than the other
groups; the effects of GWAS SNP heritability are
the most influential at a young age while the ef-
fects of environmental factors increase with time. In
conclusion, a prediction model using both GWAS
data and family history can help predict the
development of allergic diseases. Consideration of
family history may enhance predictive perfor-
mance when accompanied with genetic risk of
allergic diseases.Abbreviations
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